Biotechnology
Commented by Carsten Mainitz on January 20th, 2022 | 12:14 CET
Evotec, Defence Therapeutics, Formycon - Who will benefit from Omicron?
The Coronavirus has shown that without biotechnology and ongoing research, we are relatively defenseless against the whims of nature. What would have happened if novel technology had not been available to produce potent vaccines in a very short time? Would our intensive care units have been as crowded as they were in Italy at the beginning of the pandemic? Would hospital triage be the norm today? No one can say for sure, but history has shown how epidemics - such as the Spanish flu - have claimed many lives in the past.
Read
Commented by Stefan Feulner on January 20th, 2022 | 09:15 CET
Valneva, XPhyto, BioNTech - This is the breakthrough
The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.
Read
Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET
BioNTech, Defence Therapeutics, PAION - Seizing the momentum
The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.
Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
Read
Commented by André Will-Laudien on January 12th, 2022 | 11:03 CET
Valneva, Cardiol Therapeutics, Novavax: Hitting the nail on the head!
What is the correlation between the development of drugs or vaccines and the price of the company in question on the stock market? Difficult to answer because there is an almost infinite number of research areas in the field of biotechnology. Not all of them are at the center of media interest, while some topics, in contrast, experience true hype phases. COVID-19 is a viral disease that is to be overcome with all available research resources, and the attention on the capital markets is correspondingly high. Those who can demonstrate success in this area achieve high prices and valuations. But who will deliver the ultimate vaccine or a revolutionary drug to treat infected people? Lots of speculation, risks and opportunities in equal measure. We take a look at some interesting companies.
Read
Commented by Nico Popp on January 7th, 2022 | 12:51 CET
BioNTech, XPhyto, Valneva: 3 stocks for next week?
Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.
Read
Commented by Carsten Mainitz on December 28th, 2021 | 11:26 CET
Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!
The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.
Read
Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET
BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming
The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.
Read
Commented by Nico Popp on December 22nd, 2021 | 13:50 CET
BioNTech, Novavax, Cardiol Therapeutics: This pandemic profiteer is as cheap as can be
Omicron is coming; that much seems certain. But what does the virus mean for the stock market? Currently, the forecasts of the modelers are dominating the news. While some see it as scaremongering, others consider epidemiological models a rational approximation of what we face. Like a crystal ball, so to speak, but without the hocus-pocus. To assess the situation as an investor, it makes sense to assume neither the best nor the worst. We analyze the current viral situation and explain what this could mean for typical Corona stocks.
Read
Commented by Armin Schulz on December 15th, 2021 | 11:35 CET
Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated
In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.
Read